JP2022516974A5 - - Google Patents
Info
- Publication number
- JP2022516974A5 JP2022516974A5 JP2021539935A JP2021539935A JP2022516974A5 JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5 JP 2021539935 A JP2021539935 A JP 2021539935A JP 2021539935 A JP2021539935 A JP 2021539935A JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- active agent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059887A JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790326P | 2019-01-09 | 2019-01-09 | |
| US62/790,326 | 2019-01-09 | ||
| PCT/US2020/012647 WO2020146440A1 (en) | 2019-01-09 | 2020-01-08 | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Division JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516974A JP2022516974A (ja) | 2022-03-03 |
| JP2022516974A5 true JP2022516974A5 (cg-RX-API-DMAC7.html) | 2023-01-24 |
| JP7467479B2 JP7467479B2 (ja) | 2024-04-15 |
Family
ID=69500830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539935A Active JP7467479B2 (ja) | 2019-01-09 | 2020-01-08 | 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 |
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 |
Country Status (23)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010556A (es) * | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| DK3908281T3 (da) * | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| EP4297750A1 (en) * | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| KR20240013793A (ko) * | 2021-05-27 | 2024-01-30 | 셀진 코포레이션 | 조합 요법을 사용하는 다발성 골수종의 치료 방법 |
| US20230142647A1 (en) * | 2021-07-12 | 2023-05-11 | Quteba Ebrahem | Method of treating cancer or a blood disorder |
| US20250032483A1 (en) * | 2021-12-03 | 2025-01-30 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating pain |
| CN116496246A (zh) * | 2022-01-18 | 2023-07-28 | 中国药科大学 | 异吲哚啉类化合物、制备方法、药物组合物和应用 |
| CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
| CN119015299B (zh) * | 2024-08-21 | 2026-06-02 | 中国医学科学院肿瘤医院 | 西奈芬净在治疗癌症中的应用 |
| WO2026064898A1 (en) * | 2024-09-24 | 2026-04-02 | Chun Jiang | Combination therapies |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| MX2017001656A (es) | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
| US20170232030A1 (en) | 2014-08-13 | 2017-08-17 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP4201399A3 (en) * | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| PL3796912T3 (pl) * | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| DK3908281T3 (da) * | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
-
2020
- 2020-01-08 DK DK20704117.9T patent/DK3908281T3/da active
- 2020-01-08 US US16/737,710 patent/US11660297B2/en active Active
- 2020-01-08 WO PCT/US2020/012647 patent/WO2020146440A1/en not_active Ceased
- 2020-01-08 CN CN202410171019.6A patent/CN118178417A/zh active Pending
- 2020-01-08 KR KR1020217025057A patent/KR20210126011A/ko not_active Ceased
- 2020-01-08 PT PT207041179T patent/PT3908281T/pt unknown
- 2020-01-08 IL IL284671A patent/IL284671B2/en unknown
- 2020-01-08 SI SI202130207T patent/SI3908281T1/sl unknown
- 2020-01-08 SM SM20240388T patent/SMT202400388T1/it unknown
- 2020-01-08 CN CN202210009586.2A patent/CN114404596A/zh active Pending
- 2020-01-08 HR HRP20241309TT patent/HRP20241309T1/hr unknown
- 2020-01-08 HU HUE20704117A patent/HUE068895T2/hu unknown
- 2020-01-08 SG SG11202107413YA patent/SG11202107413YA/en unknown
- 2020-01-08 MX MX2021008294A patent/MX2021008294A/es unknown
- 2020-01-08 RS RS20241127A patent/RS66066B1/sr unknown
- 2020-01-08 CN CN202080018980.1A patent/CN113543786A/zh active Pending
- 2020-01-08 JP JP2021539935A patent/JP7467479B2/ja active Active
- 2020-01-08 ES ES20704117T patent/ES2995189T3/es active Active
- 2020-01-08 FI FIEP20704117.9T patent/FI3908281T3/fi active
- 2020-01-08 LT LTEPPCT/US2020/012647T patent/LT3908281T/lt unknown
- 2020-01-08 EP EP20704117.9A patent/EP3908281B9/en active Active
- 2020-01-08 CA CA3125753A patent/CA3125753A1/en active Pending
- 2020-01-08 PL PL20704117.9T patent/PL3908281T3/pl unknown
- 2020-01-08 AU AU2020205643A patent/AU2020205643C1/en active Active
- 2020-01-08 EP EP24191518.0A patent/EP4461370A3/en active Pending
- 2020-01-08 EA EA202191903A patent/EA202191903A1/ru unknown
-
2021
- 2021-07-08 MX MX2024008439A patent/MX2024008439A/es unknown
-
2023
- 2023-04-25 US US18/139,151 patent/US12186311B2/en active Active
-
2024
- 2024-04-03 JP JP2024059887A patent/JP2024081769A/ja active Pending
- 2024-11-21 US US18/955,085 patent/US20250082629A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230190760A1 (en) | Advantageous therapies for disorders mediated by ikaros or aiolos | |
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| JP2022546471A5 (cg-RX-API-DMAC7.html) | ||
| FI3908281T3 (fi) | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa | |
| JP2023515817A (ja) | ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ | |
| KR20180113976A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| JP2024501471A5 (cg-RX-API-DMAC7.html) | ||
| JP2022552880A (ja) | 置換4-アミノイソインドリン-1,3-ジオン化合物および組合せ使用のための第2の活性剤 | |
| CN101511357A (zh) | 治疗和预防眼部疾病的方法 | |
| JP2018530578A (ja) | 組み合せ抗細菌組成物および短期抗細菌レジメン | |
| CN107406413A (zh) | C21H22Cl2N4O2的晶型 | |
| CN118201615A (zh) | 喹唑啉酮化合物用于治疗癌症的新用途 | |
| JP2022535893A5 (cg-RX-API-DMAC7.html) | ||
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| KR101307650B1 (ko) | 구역에 대한 경피 방법 및 패치 | |
| JP2018525411A (ja) | 多発性骨髄腫を治療するためのbtk阻害剤の組み合わせ | |
| BR112018074381B1 (pt) | [8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il) metanonas, seu uso e seus métodos de preparação, composição e combinação farmacêutica, intermediários e seu uso | |
| US9951041B2 (en) | Crystalline C21H22Cl2N4O2 malonate | |
| EP0528749B1 (en) | Indole derivatives and their use | |
| WO2018213770A1 (en) | Therapeutic methods | |
| CN121969357A (zh) | Mrtx1133药物组合物 | |
| JP2018515507A5 (cg-RX-API-DMAC7.html) | ||
| RU2006126828A (ru) | Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза | |
| AU2021401681A1 (en) | Dosing of fedratinib |